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REVIEW
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Tkachev Clinic, Volgograd, Russia
ABSTRACT
Introduction: Paracetamol is one of the most frequently used analgesics for people with low back pain, 
but despite its frequent use there is still debate regarding its efficacy and safety for this indication.
Areas covered: We describe the origin of paracetamol and its proposed mechanisms of action. We 
focus in on low back pain and describe the evidence it has on the efficacy of paracetamol (taken by 
patients orally) and current insights on its side-effects. When searching for relevant publications we 
focused mainly on recent Cochrane reviews and published RCTs. We found that there is increasing 
evidence that shows paracetamol is not more effective than placebo in patients with acute low back 
pain. Concerning patients with subacute and chronic back pain, the evidence for or against the efficacy 
of paracetamol vs placebo is lacking and would need more research.
Expert opinion: We argue that we still need better evidence on the efficacy of paracetamol for acute 
and chronic back pain. Until that evidence becomes available paracetamol should still be considered as 
an option for patients with back pain. However, we suggest that a strategy focusing on non- 
pharmacological management as the first treatment option in low back pain may be equally effective 
with less side effects.
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1. Introduction
Paracetamol (P) has been available for the management of 
pain for more than 100 years. It is reported that it was already 
synthesized in the year 1878 [1,2]. The initial clinical results of 
paracetamol were published in 1893 by a German physician 
but were not positive. Von Mering reported that adverse 
effects of paracetamol were elevated blood levels of methe-
moglobin which could lead to dangerous tissue hypoxia [3]. 
Because of this serious adverse event and due to the avail-
ability of another drug, namely aspirin (since 1899), paraceta-
mol did not receive much attention.
This situation changed around 1948 when Merings’ claims 
were disputed by British and American scientists who sug-
gested that paracetamol could well be used as an analgesic 
and antipyretic [4–6] These scientist showed that the pre-
viously found methemoglobin in patients that used paraceta-
mol was attributed to contamination of the paracetamol; 
purified paracetamol did not yield this dangerous side-effect. 
Paracetamol subsequently entered the marked in the 1950s in 
the USA and since then its popularity strongly increased. 
Around 1980 paracetamol was sold more often over the coun-
ter than aspirin in the United Kingdom [1]. In 2014, more than 
200 million packs of paracetamol were sold in the UK [7]. 
Nowadays paracetamol is amongst the most frequently used 
drugs worldwide and presents in most households for the 
treatment of acute and chronic pain conditions. This review 
article summarizes the mechanism of action of paracetamol 
and describes the evidence from RCTs regarding the efficacy 
of paracetamol (via oral route) for people with low back pain 
as compared to placebo and NSAIDS. Hereafter, we described 
the outcomes of the PACE-trial, which is the largest RCT 
evaluating the efficacy of paracetamol versus placebo for 
people with acute low back pain. Next, we present data 
regarding potential harms of paracetamol. Subsequently, we 
consider which recommendations regarding the prescription 
of paracetamol are included in recent clinical guidelines for 
the management of low back pain. After a short summary of 
the efficacy and harms of NSAIDs, which are regarded as an 
alternative for paracetamol, we present our own opinion. 
When searching for relevant publication we were mainly look-
ing at recent (Cochrane) reviews and published RCTs (e.g. the 
PACE-study).
2. Mechanism
For decades it was assumed that paracetamol inhibits pro- 
inflammatory prostaglandin (PG) synthesis via the inhibition 
of cyclooxygenase enzyme (COX). However, current studies 
demonstrate low inhibitory action of P both on COX-1 and 
COX-2, though its clinical efficacy is high and is associated 
with pronounced antipyretic and analgesic effect, compared 
to other compounds [8,9]. This fact makes the elucidation of 
the mechanism of action of paracetamol challenging but 
explains almost complete absence of anti-inflammatory action 
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of the drug (anti-inflammatory action of a number of drugs is 
associated with COX-2 inhibition).
Recently, two mechanisms of paracetamol action were 
hypothesized. Graham et al. [10] report, that paracetamol has 
almost negligible action on COX-1 and COX-2 in vitro, but 
postulate that in vivo paracetamol blocks biological effects 
of PGs in intact cells directly by decreasing the concentration 
of arachidonic acid. Paracetamol action on PG synthesis may 
be realized through the modulation of stimulating action of 
pro-inflammatory cytokines [10].
Other researchers suggest that paracetamol is a specific 
and unique COX-3 inhibitor [9]. It is assumed that COX-3 
plays a role in later phases of inflammatory process via the 
modulation of the synthesis of endogenous anti-inflammatory 
mediators [11,12]. Paracetamol action may be associated also 
with central mechanisms that is mediated though activation of 
descending serotonergic pathways and through an active 
metabolite influencing cannabinoid receptors, other than 
downregulation of PG synthesis [13]. A recent FMRI study 
also suggests a central effect of paracetamol in cerebral 
areas know to be associated with pain [14]
3. Low back pain
Low back pain is a musculoskeletal condition for which para-
cetamol is prescribed and used regularly. Low back pain 
occurs frequently and is responsible for a substantial burden 
of illness. It is the number one condition responsible for years 
lived with disability (YLDs) [15]. Almost everybody, up to 
80–90% of the population, will experience an episode of low 
back pain during their life. In most cases with acute low back 
pain, the prognosis is favorable and the pain and related 
disability will diminish within a few week. In a small percen-
tage (5–10%), however, the low back pain persists and devel-
ops in a chronic pain disorder. Low back pain is also 
characterized by its recurrences. After recovery of a low-back 
pain episode the complaints often (up to a third of the cases) 
return in the following year [15].
In most people with low back pain, the precise cause of the 
pain is unknown. In only a small proportion (up to 5–10%) of 
patients presenting in primary care underlying pathologies, 
such as malignancies, fracture, infections can be identified. 
When specific pathologies explaining the back pain are not 
present, the complaints are labeled as being nonspecific. It 
hampers adequate treatment that in most cases no cause of 
the pain can be found, since no causal treatment can thus be 
applied. Consequently, many treatments for low back pain are 
focused on reduction of symptoms. There are many treat-
ments available for people with back pain. This includes non- 
pharmacological treatments (patient education, exercises, 
manual therapies) and pharmacological treatments (mostly 
pain medications, including paracetamol) [16]. Some patients 
suffering from low back pain also receive surgery. Especially 
patients with persisting radicular pain (>6–8 weeks) in the leg 
due to a herniated disk are regarded as surgical candidates. At 
the same time, there is good evidence that recovery rates after 
1 and 2 years follow up are more or less similar between 
patients receiving disc surgery or prolonged conservative 
care [17]
4. Analgesics for low back pain
Analgesics are frequently prescribed for people with back pain. 
An estimated 55% of the patients with low back pain use analge-
sics [18]. In a cohort study in elderly people presenting with back 
pain in primary care this percentage was 72% [19]. Data from 
Australia shows that 892 analgesics were recommended per 
1000 spinal pain problems [20]. In Switzerland a study showed 
that the most prescribed medications for low back pain were 
non-steroidal anti-inflammatory drug (NSAIDs) in 97.4 of the 
respondents followed by paracetamol in 94.4% of the respon-
dents [21]; other drugs that are often recommended for low back 
pain are opioids, muscle relaxants and anti-depressants [22] 
Bearing in mind that these data concern prescriptions and not 
over-the-counter medications, the actual use of analgesics, 
including paracetamol, in people with back pain is very common. 
Of concern, especially because of the frequent use of analgesics 
such as paracetamol and NSAIDs, are the potential harms of 
these drugs. The harms of paracetamol are described elsewhere 
in this review. The potential harms of NSAIDs, the increased risk 
of gastrointestinal side effects, are well known and should be 
considered when managing elderly patients.
5. Evidence of benefits
5.1. Paracetamol versus placebo
The Cochrane review (2016) on paracetamol for low back pain 
summarized the available evidence on the efficacy [23]. This 
Cochrane review only included placebo-controlled studies and 
initially identified three studies. One study [24] was a large 
study from Australia, the second study [25] was from the 
United states and the third study [26] was from Austria. 
However, the last study [26] has been retracted from the 
literature (one of the authors had not consented to submis-
sion and publication of the study). Meta-analysis was not 
possible in the Cochrane review because the study by Nadler 
did not report results for the placebo group. The main con-
clusion of the Cochrane review were that in patients with 
acute low back pain, paracetamol was not better than placebo 
and there was uncertainty regarding the effect in patients with 
chronic low back pain.
Table 1 presents the currently available randomized clinical 
trials evaluating paracetamol vs placebo in patients with acute 
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low back pain. The studies by Nadler, and Williams were 
included in the Cochrane review [23–25]. The study by 
Friedman was published afterward [27]. Table 1 illustrates 
the overall limited evidence available comparing paracetamol 
versus placebo. In total, only three trials were conducted in 
patients with acute low back pain, for one of which no data 
were presented on the placebo group. The two remaining 
trials show that there is no difference in effect of paracetamol 
versus placebo. This holds true for paracetamol taken regu-
larly, as needed and as addition to Ibuprofen [24,27]. For 
chronic low back pain, there was only one trial, but the pub-
lication of this study has been retracted [26], thus for chronic 
low back there is no good evidence for or against the efficacy 
of paracetamol available.
5.2. Paracetamol versus NSAIDs
The previous Cochrane review on NSAIDs for low back pain 
(2008) covered acute as well as chronic low back pain [28]. 
This review has subsequently been split up in one review 
focusing on acute low back pain [29], one on chronic low 
back pain [30,31] and one on sciatica [32,33].
There are only limited trials available comparing NSAIDs 
with paracetamol. Table 2 shows three trials in acute low 
back pain and one in chronic low back pain. Most of the 
studies are relatively old, show methodological shortcomings 
(e.g. a drop-out rate of 45%) and are carried out in specific 
study populations (e.g. young soldiers who were prescribed 
bedrest). The three trials in people with acute low back pain 
show no significant differences in effect (pain and disability) 
between NSAIDs and paracetamol [25,34,35]. There is only one 
trial in people with chronic low back pain in which an NSAID is 
compared to paracetamol. In this relatively old study (1982), 
diflunisal (1000 mg/day) was compared to paracetamol 
(4000 mg/day). The study had a small sample size (n = 30) 
and did not find significant differences between the NSAID 
and paracetamol [36]. The authors of the Cochrane review 
(chronic low back pain) conclude that it remains unclear 
whether NSAIDs are more effective than other drugs, including 
paracetamol [30,31].
5.3. The PACE – trial
Overall, Tables 1 and 2 show a limited number of relatively old 
trials with small sample sizes and methodological shortcom-
ings. There is one more recent Australian trial which stands 
out regarding size and methodological quality and also 
regarding the impact on recommendations in clinical guide-
lines as well as on clinical practice. This so-called PACE-trial 
was published in 2014 in the Lancet [24]. Up to that date, 
there was no good evidence available regarding the efficacy of 
paracetamol for acute low back pain, despite the fact that 
paracetamol was recommended in most (inter)national clinical 
guideline for the management of low back pain as the pre-
ferred first choice of pain medication, if prescription of pain 
medication was considered [37,38]. The PACE trial was con-
ducted in Sydney, Australia and included 1652 people with 
acute low back pain. Patients had a new episode of low back 
pain with or without leg pain of at least moderate intensity. 
Patients were randomly allocated to three groups; (1) parace-
tamol (two tablets of 665 mg modified release paracetamol 
three times a day) regularly (n = 550); (2) paracetamol (two 
tablets of 500 mg immediate release tablets taken up to four 
times a day) as needed (n = 549) or (3) placebo (n = 553) for 
a maximum of four weeks or until recovery, if this happened 
before the four-week time point. Patients, clinicians and 
researchers were blind regarding the treatment allocation. 
Patients received instruction to use the study medications 
until they had experienced seven consecutive days with no 
or limited pain (0 or 1 on a 0–10 pain scale) or for maximum of 
Table 1. RCTs evaluating paracetamol vs placebo in patients with acute low back pain.





(1) heat wrap 
(2) ibuprofen (1200 mg/d) 
(3) paracetamol (4000 mg/d) 
(4) placebo 
(5) unheated back wrap 
All interventions for 2 days
Pain relief (NRS 0–5); Disability 
(RMDQ 0–24)
No data on the placebo group 
presented. 
Pain relief after 3–4 days: group 
2 (1.68) 
group 3 (1.95) 
Disability after 3–4 days: 






(1) paracetamol regular (3990 mg/d) 
(2) paracetamol as needed (max 
4000 mg/d) 
(3) placebo 
All interventions max 4 weeks
Pain (NRS 0–10); Disability 
(RMDQ 0–24)
No difference in outcome between 
the 3 groups. 
Pain intensity after 2 weeks: 
Group 1 (2.6) 
Group 2 (2.6) 
Group 3 (2.5) 
Mean disability afer 2 weeks: 
Group 1 (5.2) 
Group 2 (5.4) 
Group 3 (5.3)
Median days to 
recovery 
Group 1(17) 






(1) Ibuprofen (600 mg) + paracetamol 
(2000–4000 mg) 
(2) Ibuprofen (600 mg) + placebo 
Both interventions for 7 days
Disability (RMDQ 0–24) Pain 
(4-point scale)
No difference in outcome between 
the 2 group 
Pain after one week none/mild: 
Group 1 (72%) 
Group 2 (72%) 
Improvement disability: 
Group 1 (11.1) 
Group 2 (11.9)
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four weeks. On the primary outcome measure, which was time 
to recovery, no difference in effect between the three groups 
was found; the median time to recovery was 17 days in the 
regular group, 17 days in the as-needed group and 16 days in 
the placebo groups. Also on the secondary outcome mea-
sures, including pain intensity, disability, health-related quality 
of life the study showed no significant and/or clinically rele-
vant difference between the three study groups [24].
5.4. Replication of the PACE-trial
Due to the importance and impact of the PACE trial for 
patients and clinicians, replication of the study and its results 
are important. Unfortunately, a subsequent attempt to repli-
cate the PACE-trial, namely the PACE-plus trial was discontin-
ued due to problems with patient recruitment [37]. It was 
however, possible to conduct a re-analysis of the original 
data of the PACE study using the predefined and published 
protocol of the PACE-plus study, including its statistical analy-
sis plan [39]. In this so-called inferential reproducibility study, 
conducted by an independent group, a different primary out-
come was chosen, namely pain intensity (0–10 NRS), data from 
pain diaries were used instead of data from follow-up ques-
tionnaires, a different statistical approach was used and pre-
planned exploratory subgroup analyses (based on severe pain 
intensity NRS >7 and severe impairment of physical function-
ing (RMDQ > 16)) were included. The re-analysis showed that 
paracetamol, either taken regular or as needed, was not more 
effective than placebo in reducing the pain intensity (primary 
outcome) and secondary outcomes such as physical function-
ing and health-related quality of life and time to recovery. 
These results (i.e. no difference between paracetamol vs pla-
cebo) were also found in the subgroups of patients with 
severe pain-intensity and severe impairment of physical func-
tioning. Overall, the re-analysis confirmed the original analysis 
and results of the PACE-trial and strengthen its conclu-
sions [40].
5.5. Influence of compliance in the PACE-trial
One point of discussion after the publication of the PACE trial 
was the potential influence of (non)compliance regarding 
medication intake on the study results. Non-adherence was 
discussed in the original publication of the trial as well as in 
subsequent commentaries. There were reports that up to 70% 
of patients in PACE were non-adherent (depending on the 
definition of non-adherence) during the study period and 
the overall adherence to guideline recommended care was 
considered as poor [41]. In order to investigate the influence 
of noncompliance on the outcomes in the PACE trial 
a Complier Average Causal Effect (CACE-)analysis was carried 
out. In a CACE-analysis, patients randomized to the interven-
tion group who are compliant are compared to patients ran-
domized to the control group, who would have been 
compliant if they had been randomized to the intervention 
group. In the CACE-analysis of the PACE study, data were used 
of the patients randomized to the regular paracetamol treat-
ments versus the patients in the placebo group. Compliance 
Table 2. RCTs evaluating paracetamol vs NSAIDs in patients with acute or chronic low back pain.
Author(s), year patients interventions Outcomes/follow-up Results Remarks
Wiesel 1980 
[34]
Acute LBP  
(n = 45)




(100 mg- 4times/ 
d) 
(3) paracetamol (1 
tablet (?mg) 2 
times/d 
All intervention for 
5 days
Pain; No days before return 
work/follow-up 2 weeks
No significant differences. Mean 
number of days before return work 
group 1 (5.7) 
group 2 (6.5) 
group 3(5.7)
(1)concerns soldiers (age 17–34) 




Acute LBP  
(n = 371)






(5) unheated back 
wrap 
All interventions for 
2 days
Pain relief (NRS 0–5); 
Disability (RMDQ 0–24)/ 
follow up 4 days
No difference (2) vs (3) regarding pain 
and disability 
Pain relief after 3–4 days: group 2 
(1.68) 
group 3 (1.95) 
Disability after 3–4 days: 
group 2 (2.7) 
group 3 (2.9)
Miki 2018 [35] Acute LBP 
(n = 127)
(1) loxoprofen 
(60 mg-3 times/d) 
(2) paracetamol 




Pain (NRS)/follow up 4 weeks No significant differences 
Mean difference I pain score 
Group 1 (−0.5) 
Group 2 (0)











No. of patient with none/mild 
back pain
No difference between the groups. 
No. of patient with none/mild back 
pain after 2,4 weeks 
Group 1 (11,13) 
Group 2 (9,7)
More patients rated (1) as good or 
excellent (10 out of 16 vs 4 out 
of 12)
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was defined as taking at least an average of four out of six 
prescribed tablets (corresponding to 2660 mg in total) per 
participant per day during the first two weeks after inclusion 
in the PACE trial. Based on this definition 394 (72%) compliers 
were identified in the regular paracetamol group. The results 
showed that for the primary outcome measure pain intensity 
(0–10 NRS) the mean difference between the regular parace-
tamol group and the placebo group was 0.068 (95% CI −0.37, 
0.50) in the propensity weighted CACE-analysis, 0.23 (95% CI 
−0.16, 0.62) in the Joint Modeling CACE-analysis and 0.11 (95% 
CI −0.20, 0.42) in the Intention-to-treat analysis. All these 
differences were not statistically nor clinically significantly 
different. The analysis of the secondary outcome measures, 
disability, physical functioning, global change showed similar 
findings. These results showed that even in patients compliant 
to the treatment regimen paracetamol was not more effective 
than placebo [42].
6. Evidence of harms of paracetamol
When considering the value of medication, it is important to 
consider the potential benefits as well as the potential harms. 
Traditionally, paracetamol has been considered to be 
a relatively safe type of medication which is one of the reasons 
why it has been recommended as the first step in the pain 
ladder of the World Health Organization (WHO) and also as the 
recommended first choice of pain medication in (inter)national 
clinical guidelines for the management of back pain [37]). In 
the efficacy studies presented above, only limited data on 
side-effects are included and presented. These studies are 
not set up, nor have the size to validly and reliably estimate 
the safety of paracetamol for patient with back pain. The 
prevalence and severity of harms should preferably come 
from other sources such as large cohort studies, patient regis-
tries, (inter)national surveillance studies. A recent review arti-
cle summarized long-term adverse effects of paracetamol [1]. 
They reported that there is evidence for an increased risk of 
gastrointestinal bleeding (paracetamol taken regularly at 
doses >2–3 g per day) and a small increase in systolic blood 
pressure (4 mmHg), but these associations need further con-
firmation including in randomized clinical trials. The authors 
conclude that in the management of chronic pain disorders 
paracetamol can be regarded as the least worse option, when 
compared with other options, such as NSAIDs and opioids [1].
In a review of eight cohort studies Roberts et al. report on 
increased risk of side effects of paracetamol. Four of these 
studies reported on cardiovascular side-effects and showed 
a dose–response with one study reporting an increased risk 
ratio of all cardiovascular side-effects ranging from 1.19 (0.81 
to 1.75) to 1.68 (1.10 to 2.57). One cohort study reported on 
increased risk of gastrointestinal side effects and reported 
a dose–response (an increased risk ranging from 1.11 (1.04 
to 1.18) to 1.49 (1.34 to 1.66)). Four cohort studies reporting 
renal side effect, of these three reported a dose–response with 
one reporting an increasing OR of ≥30% decrease in estimated 
glomerular filtration rate from 1.40 (0.79 to 2.48) to 2.19 (1.4 to 
3.43). The authors of the review mention the observational 
nature of the data and the possibility of channeling bias, but 
(based on the found dose–response relationships) they warn 
for the increased risk of side-effects, especially when using 
higher analgesic dosages [43]. In 2011 the FDA recommended 
that the paracetamol dosage unit for a prescription should be 
325 mg or less. Since January 2014 this is obligatory for 
manufacturers [44]. There seems to be consensus that the 
maximum daily dosage of paracetamol should not exceed 
4000 mg. Also, in all RCTs, including the large PACE-trial, 
described in this review and presented in Tables 1 and 2 the 
prescribed daily dosages of paracetamol not higher than 
4000 mg.
7. Recommendations in clinical guidelines
Many national clinical guidelines contain recommendations 
regarding the use of paracetamol for symptomatic pain treat-
ment in patients with back pain. For decades, paracetamol was 
the undisputed analgesic of first choice, if prescription of pain 
medication was considered [22,37,45]. More recently, there 
appears to be more variation in the recommendations. While in 
some guidelines paracetamol remains a first choice, in other 
guidelines paracetamol is not recommended (any more). It is of 
interest to see which recommendations are included in guide-
lines issued from 2016 onwards. The PACE trial was published in 
2014 and its results could well have influenced the recommen-
dations in the guidelines published in 2016 and more recently 
[22,45]. Table 3 presents an overview of the recommendations 
regarding paracetamol in these recently issued clinical guide-
lines. In four out of eight guidelines paracetamol is not recom-
mended, whereas in three guidelines it is still recommended and 
in one guideline it is considered optional, but it is mentioned that 
there is evidence of a lack of effect. Based on the same body of 
evidence, Table 3 thus shows that guideline committees decided 
to give different and sometimes even opposite recommenda-
tions. The new evidence, especially from the large PACE-trial 
Table 3. Paracetamol recommendation in recent (2016 onwards) clinical guidelines for back pain.
Country Recommendation concerning paracetamol for back pain
Australia, 2016 Recommended for acute low back pain – but information is included that there is evidence that paracetamol may not be more effective 
than placebo
Belgium, 2017 Not recommended as single pain medication
Canada, 2017 Recommended as first choice pain medication for acute and chronic back pain. NSAIDs are second choice.
Denmark, 2018 Only after careful consideration in patients with acute low back, because of evidence of no short term effect
Germany, 2017 Not recommended due to new evidence of lack of effect compared to placebo
The Netherlands, 
2017
May be prescribed regularly or as-needed; NSAIDS may not be more effective than paracetamol
UK, 2017 Not recommended
US, 2017 Not recommended due to new evidence indicating that paracetamol is not more effective than placebo
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certainly resulted in a less favorite role of paracetamol in many 
recent guidelines.
8. Alternatives for paracetamol
8.1. NSAIDs
In many clinical guidelines NSAIDs are recommended 
as second choice pain medication for patients with back 
pain. In a few guidelines, NSAIDS have replaced paracetamol 
as first option. NSAIDS are often prescribed but are also avail-
able over the counter [46].
8.2. NSAIDS vs placebo
The Cochrane review on NSAIDs for acute low back pain 
included 9 trials comparing NSAIDs with placebo [29]. The 
results showed that NSAIDs were significantly more effective 
than placebo. However, the mean difference in pain intensity 
score between NSAIDs and placebo (based on statistical pool-
ing of four trials) was about 7 points (i.e. −7.29 (95% CI −10.98 
to −3.61) on a 0 to 100 pain scale. Also regarding physical 
functioning as measured with the Roland Morris Disability 
Questionnaire (RMDQ) NSAIDs were found to be significantly, 
but only marginally more effective than placebo. The mean 
difference (based on two trials) was about 2 points (i.e. −2.02 
(95% CI −2.89 to −1.15) on a scale from 0 to 24. The Cochrane 
review concludes that NSAIDs are (slightly) more effective 
than placebo regarding pain intensity and disability.
The Cochrane review on NSAIDs for chronic low back pain 
(2016) included six trials comparing NSAIDs with placebo 
[30,31]. The results showed that NSAIDs were significantly 
but clinically only marginally more effective than placebo. 
The mean difference in pain intensity score between NSAIDs 
and placebo was only about 7 points (i.e. −6.97 (95% CI −10.74 
to −3.19) on a 0 to 100 pain scale. Also regarding physical 
functioning as measured with the Roland Morris Disability 
Questionnaire (RMDQ) in four studies, NSAIDs were found to 
be significantly, but only marginally more effective than pla-
cebo. The mean difference was less than 1 point (i.e. −0.85 
(95% CI −1.30 to −0.40) on a scale from 0 to 24. The Cochrane 
review concludes that NSAIDs are (slightly) more effective 
than placebo regarding pain intensity and disability. 
However, the magnitude of the effects is small and if only 
RCTs with a low risk of bias are considered, the differences in 
effect between NSAIDs and placebo are even smaller [30,31].
The safety profile of NSAIDs in general is considered to be 
less favorable compared to paracetamol. Therapeutic effects of 
NSAIDs are associated with their ability to block COX-2, 
whereas the most common adverse effects (digestive system 
disorders, renal damage, impairment of platelet aggregation, 
etc.) – with decreased COX-1 activity. Among the most widely 
used NSAIDS those with selective action on COX-2 are asso-
ciated with 3-4-fold fewer gastro-intestinal side-effects, com-
pared to nonselective NSAIDS
Of importance is to mention the value of an evaluation of 
the cytochrome P450 (CYP450) system. Some patients with 
deficit enzyme defects may not benefit from the NSAIDS 
which use the CYP450-2C9 or CYP450-3A4 as substrates [44].
9. Ongoing studies
A check on ongoing studies evaluating the efficacy of para-
cetamol for back pain on www.clinicaltrials.gov revealed that 
most of the current studies focus on combination drugs, e.g. 
tramadol hydrochlorine/paracetamol; codeine/paracetamol; 
orphenadrine, caffeine, diclofenac sodium/paracetamol; or 
hydrocodone/paracetamol. Studies evaluating (oral) paraceta-
mol as mono-drug for back pain are hardly conducted.
10. Expert opinion
This review concerning the current status of paracetamol 
shows the different views that clinicians and guideline devel-
opers have on its value in the management for patients with 
back pain. This review showed that there is increasing evi-
dence that paracetamol is not more effective than placebo in 
patients with acute low back pain. The large and well con-
ducted Australian PACE-trial found no difference in effect of 
regular paracetamol, paracetamol as-needed and placebo. 
Subsequently, independent re-analysis of the data confirmed 
the conclusion of no effect and also in subsequent analyses 
focusing on compliant patients, no effect could be demon-
strated. The PACE trial gives a strong message. At the same 
time, it remains a single trial, conducted in a single country 
and setting only. In order obtain a stronger evidence regard-
ing the evidence of paracetamol for acute low back pain 
a replica study with new data in a another setting/country 
would be welcome. The recent trial by Friedman et al. also 
found no difference in effect of paracetamol versus placebo, 
but their study design (e.g. both paracetamol and placebo 
were given in combination with Ibuprofen) and setting was 
quite different from the PACE-trial hampering statistical pool-
ing of the results of both trials.
Concerning patients with subacute (between 6 and 
12 weeks) and chronic (>12 weeks) back pain, the evidence 
for or against the efficacy of paracetamol vs placebo unfortu-
nately is lacking. We cannot simply generalize the finding in 
patients with acute back pain to those with subacute and 
chronic back pain. Further high quality evidence from rando-
mized clinical trials in patients with subacute and chronic back 
pain is clearly needed.
An important issue is whether paracetamol should be 
recommended (e.g. in clinical guidelines) and used in clinical 
practice in the management of back pain. At least 2 questions 
are relevant for this issue: (1) What are the alternatives? and (2) 
What is the magnitude of the placebo-effect?
(1) When considering the alternatives, the option of non- 
pharmacological care, i.e. not prescribing or taking pain 
medication is an important one. Especially for patients with 
acute back pain, it is known that their prognosis is favor-
able as illustrated by the median recovery rates (about 
17 days) in the PACE trial. For many patients, it holds that 
with adequate patient education and reassurance and with 
their pain diminishing relatively quickly over time there is 
no need for taking pain medications. In the American 
guidelines, non-pharmacological care is explicitly recom-
mended as the first option in the management of back 
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pain. For those patients in which pain medication is con-
sidered (if the non-pharmacological was insufficient), 
NSAIDs are proposed as alternative for paracetamol and 
are thus recommended as first option as pain medication 
in some clinical guidelines. The present review, however, 
showed that effect of NSAIDS on pain and disability were 
very small and most likely not clinically relevant. Moreover, 
in head-to-head comparisons, NSAIDS have not shown to 
be clearly better than placebo, although the number of 
trials investigating this contrast is rather limited. Given 
these findings and because the safety profile of NSAIDS is 
less favorable than the safety profile of paracetamol, it is 
not obvious that NSAIDS should be preferred.
(2) In research, we often want to separate specific effects of 
medications from nonspecific effects or placebo effects. In 
clinical practice, this distinction may be less relevant. 
Medication is prescribed to and used by patients and 
the end-results may be caused by the specific as well as 
the nonspecific effect of the drug – the more effect the 
better. By discarding paracetamol as pain medication for 
patients with back pain we also lose the potential of the 
nonspecific effects. While indeed there are ethical issues 
involved in prescribing placebo it is important to 
acknowledge that placebo-effects are true and measur-
able effects. There are even open-label placebo trials in 
the field of back pain, in which patients are told that they 
would receive placebo, which show positive effects on 
pain and disability [47,48]. On the other hand, we know 
that placebo-effects in trials may be exceeding 30% of the 
total observed effect, and that these placebo effects may 
not be reflected in clinical practice [49]. Much is still 
unclear about the clinical relevance of the placebo effect.
In conclusion, we argue that we still are in need of better 
evidence on the efficacy of paracetamol for acute and chronic 
back pain. Until that evidence becomes available paracetamol 
should still be considered as an option for patients with back 
pain if pharmacological management is strictly necessary. 
However, a strategy focusing on non-pharmacological man-
agement as the first treatment of choice in low back pain, as 
proposed by the American clinical practice guideline may be 
equally effective with less side effects [50].
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